Etomidate

Etomidate has been studied in 2 papers since 2024: 2 trials in people; 1 in the past year. The newest paper, Nov 8, 2026: “Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia Patients”.

Intervention

2 papers study it4 more mention it3 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 6 papers on etomidate

At a glance

The findings reach people, from one lab or study. 1 lab; 1 trial, none about aging.

“The medium-dose group showed superior hemodynamic stability with smaller fluctuations in mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR)”
Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia PatientsThe Annals of pharmacotherapy2026doi:10.1177/10600280261488605

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab
  • 1 trial, none about aging
  • Human trial2

Studies in people

1 study gave etomidate to people and measured what changed.

What changedDesignPeopleSource

up: Improves hemodynamic stability

down: Decreases postoperative cognitive dysfunction8.3% POCD rate on day 1 in the medium-dose group

down: Decreases adverse events13.9% adverse events in the medium-dose group

Randomized trialintraoperative36 peopleelderlyOlder adults; hernia surgery with nerve block, sufentanil, and remimazolamThe Annals of pharmacotherapy, Nov 8, 2026

What did studies of etomidate find?

3

Studies of etomidate measured 3 outcomes: adverse events, postoperative cognitive dysfunction and hemodynamic stability.

Adverse events

downin humans1−14% adverse events in the medium-dose group

1 study
  1. Etomidate decreases adverse events in humans (13.9% adverse events in the medium-dose group).

    “Etomidate 0.2 mg/kg with nerve block achieves favorable hemodynamics and minimizes POCD and adverse reactions in elderly hernia surgery”

    Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgn = 36

    Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia Patients

    The Annals of pharmacotherapy

Postoperative cognitive dysfunction

downin humans1

1 study
  1. Etomidate decreases postoperative cognitive dysfunction in humans (8.3% POCD rate on day 1 in the medium-dose group).

    “Etomidate 0.2 mg/kg with nerve block achieves favorable hemodynamics and minimizes POCD and adverse reactions in elderly hernia surgery”

    Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgpostoperative day 1n = 36

    Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia Patients

    The Annals of pharmacotherapy

More on Postoperative cognitive dysfunction

Hemodynamic stability

upin humans1

1 study
  1. Etomidate improves hemodynamic stability in humans.

    “The medium-dose group showed superior hemodynamic stability with smaller fluctuations in mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR)”

    Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgintraoperativen = 36

    Optimal Etomidate Induction Dosage Combined With Nerve Block Minimizes Postoperative Cognitive Dysfunction and Enhances Hemodynamic Stability in Elderly Hernia Patients

    The Annals of pharmacotherapy

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 13 papers in 12 months